The Efficacy of Cimetidin for Acute - Extrinsic Atopic Dermatitis Treated With Standard Therapy

• Status: Unknown status
• Trial end date: 2020-06-30
• Target enrollment: 0
• Participant gender: All

Summary

Extrinsic - atopic dermatitis is characterized by increased of IgE serum levels. Acute extrinsic - atopic dermatitis is a type 1 hypersensitivity that involve various inflammatory mediator including Interleukin-4, Interleukin-12, and Interferon-Ɣ. Recent treatment of atopic dermatitis mainly focused on reducing the inflammation through topical and systemic regiments. However, no systemic medication could control the atopic dermatitis remission yet, and the current immunosuppressive agent used may cause many side effects if administered on a long term basis.

In the future, treatment of atopic dermatitis were specifically targeted to inhibit the role of Th2. Cimetidine is H2 receptor antihistamine that has been widely used as gastrointestinal medication for a long time. Cimetidine could modulate the immune system by activating the Th1 and lowering the Th2 activity, and lowering the IgE levels thus reducing the severity of atopic dermatitis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fakultas Kedokteran Universitas Indonesia
• Treatments: Antibodies; Cimetidine; Immunoglobulins; Interferons; Interleukin-12; Interleukin-4

Criteria

Inclusion Criteria:

• Atopic dermatitis patients diagnosed with Hanifin Rajka criteria

• Acute extrinsic atopic dermatitis

• IgE levels above 200 IU/mL

• Minimum weight 15kg

Exclusion Criteria:

• Consumption of corticosteroid and systemic immunosuppressant within the last 2 weeks

• Chronic lesion

• Consumption of drugs that reacts with cimetidine

• Disturbance in lab results including complete blood count, liver function, and renal function.

• Other conditions that might increase IgE levels